Works by Alvarado, Yesid

Results: 90
    1
    2
    3

    El mito del resultado.

    Published in:
    Nuevo Foro Penal, 2022, v. 18, n. 99, p. 37, doi. 10.17230/nfp18.99.2
    By:
    • REYES ALVARADO, YESID
    Publication type:
    Article
    4
    5
    6
    7
    8
    9

    Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia.

    Published in:
    Frontiers in Oncology, 2018, p. N.PAG, doi. 10.3389/fonc.2018.00369
    By:
    • Boddu, Prajwal;
    • Borthakur, Gautam;
    • Koneru, Mythili;
    • Huang, Xuelin;
    • Naqvi, Kiran;
    • Wierda, William;
    • Bose, Prithviraj;
    • Jabbour, Elias;
    • Estrov, Zeev;
    • Burger, Jan;
    • Alvarado, Yesid;
    • Dekmush, April;
    • Patel, Ami;
    • Cavazos, Antonio;
    • Han, Lina;
    • Cortes, Jorge E.;
    • Kantarjian, Hagop;
    • Andreeff, Michael;
    • Konopleva, Marina
    Publication type:
    Article
    10
    11
    12
    13
    14
    15
    16
    17

    Outcomes of patients with therapy‐related myeloid neoplasms after treatment with poly(ADP‐ribose) polymerase proteins inhibitors for solid tumours.

    Published in:
    British Journal of Haematology, 2023, v. 201, n. 3, p. e25, doi. 10.1111/bjh.18766
    By:
    • Almanza‐Huante, Emmanuel;
    • Bataller, Alex;
    • Urrutia, Samuel;
    • Gener‐Ricos, Georgina;
    • Briski, Robert Edward;
    • Kanagal‐Shamanna, Rashmi;
    • Lu, Karen H.;
    • Westin, Shannon N.;
    • Yap, Timothy A.;
    • Takahashi, Koichi;
    • Ravandi, Farhad;
    • Alvarado, Yesid;
    • Kadia, Tapan;
    • Sasaki, Koiji;
    • Kantarjian, Hagop M.;
    • Garcia‐Manero, Guillermo
    Publication type:
    Article
    18

    Phase II study of azacitidine with pembrolizumab in patients with intermediate‐1 or higher‐risk myelodysplastic syndrome.

    Published in:
    British Journal of Haematology, 2021, v. 195, n. 3, p. 378, doi. 10.1111/bjh.17689
    By:
    • Chien, Kelly S.;
    • Kim, Kunhwa;
    • Nogueras‐Gonzalez, Graciela M.;
    • Borthakur, Gautam;
    • Naqvi, Kiran;
    • Daver, Naval G.;
    • Montalban‐Bravo, Guillermo;
    • Cortes, Jorge E.;
    • DiNardo, Courtney D.;
    • Jabbour, Elias;
    • Alvarado, Yesid;
    • Andreeff, Michael;
    • Bose, Prithviraj;
    • Jain, Nitin;
    • Kadia, Tapan M.;
    • Huang, Xuelin;
    • Sheppard, Kimberly B.;
    • Klingner‐Winton, Cheri;
    • Pierce, Sherry A.;
    • Dong, Xiao Qin
    Publication type:
    Article
    19
    20
    21
    22

    MDS-090: Phase II Study of the IDH2 Inhibitor Enasidenib in Patients with High-Risk IDH2-Mutated Myelodysplastic Syndromes (MDS).

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S339, doi. 10.1016/S2152-2650(21)01791-2
    By:
    • Venugopal, Sangeetha;
    • DiNardo, Courtney D.;
    • Takahashi, Koichi;
    • Konopleva, Marina;
    • Loghavi, Sanam;
    • Borthakur, Gautam;
    • DeZern, Amy;
    • Masarova, Lucia;
    • Daver, Naval;
    • Short, Nicholas J.;
    • Alvarado, Yesid;
    • Ravandi, Farhad;
    • Montalban-Bravo, Guillermo;
    • Sasaki, Koji;
    • Delumpa, Ricardo;
    • Sekeres, Mikkael A.;
    • Patel, Bhumika;
    • Roboz, Gail J.;
    • Kantarjian, Hagop M.;
    • Garcia-Manero, Guillermo
    Publication type:
    Article
    23

    AML-204: Venetoclax Combined with FLAG-IDA Induction and Consolidation in Newly Diagnosed Acute Myeloid Leukemia.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S291, doi. 10.1016/S2152-2650(21)01696-7
    By:
    • Lachowiez, Curtis;
    • Koichi Takahashi;
    • Loghavi, Sanam;
    • Lianchun Xiao;
    • Kadia, Tapan;
    • Adeoti, Maria;
    • Short, Nicholas;
    • Koji Sasaki;
    • Sa Wang;
    • Borthakur, Gautam;
    • Issa, Ghayas;
    • Maiti, Abhishek;
    • Alvarado, Yesid;
    • Pemmaraju, Naveen;
    • Bravo, Guillermo Montalban;
    • Masarova, Lucia;
    • Yilmaz, Musa;
    • Nitin Jain;
    • Andreeff, Michael;
    • Jabbour, Elias
    Publication type:
    Article
    24
    25

    AML-297: Ten-Day Decitabine with Venetoclax vs Intensive Chemotherapy in Relapsed or Refractory Acute Myeloid Leukemia: A Propensity Score-Matched Analysis.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S303, doi. 10.1016/S2152-2650(21)01720-1
    By:
    • Maiti, Abhishek;
    • DiNardo, Courtney;
    • Qiao, Wei;
    • Kadia, Tapan;
    • Jabbour, Elias;
    • Rausch, Caitlin;
    • Daver, Naval;
    • Short, Nicholas;
    • Borthakur, Gautam;
    • Pemmaraju, Naveen;
    • Yilmaz, Musa;
    • Alvarado, Yesid;
    • Montalbano, Kathryn;
    • Wade, Allison;
    • Maduike, Rita;
    • Guerrero, Julio;
    • Vaughan, Kenneth;
    • Bivins, Carol;
    • Pierce, Sherry;
    • Ning, Jing
    Publication type:
    Article
    26

    Poster: MDS-090: Phase II Study of the IDH2 Inhibitor Enasidenib in Patients with High-Risk IDH2-Mutated Myelodysplastic Syndromes (MDS).

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S226, doi. 10.1016/S2152-2650(21)01427-0
    By:
    • Venugopal, Sangeetha;
    • DiNardo, Courtney D.;
    • Takahashi, Koichi;
    • Konopleva, Marina;
    • Loghavi, Sanam;
    • Borthakur, Gautam;
    • DeZern, Amy;
    • Masarova, Lucia;
    • Daver, Naval;
    • Short, Nicholas J.;
    • Alvarado, Yesid;
    • Ravandi, Farhad;
    • Montalban-Bravo, Guillermo;
    • Sasaki, Koji;
    • Delumpa, Ricardo;
    • Sekeres, Mikkael A.;
    • Patel, Bhumika;
    • Roboz, Gail J.;
    • Kantarjian, Hagop M.;
    • Garcia-Manero, Guillermo
    Publication type:
    Article
    27
    28

    Poster: AML-297: Ten-Day Decitabine with Venetoclax vs Intensive Chemotherapy in Relapsed or Refractory Acute Myeloid Leukemia: A Propensity Score-Matched Analysis.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S216, doi. 10.1016/S2152-2650(21)01362-8
    By:
    • Maiti, Abhishek;
    • DiNardo, Courtney;
    • Qiao, Wei;
    • Kadia, Tapan;
    • Jabbour, Elias;
    • Rausch, Caitlin;
    • Daver, Naval;
    • Short, Nicholas;
    • Borthakur, Gautam;
    • Pemmaraju, Naveen;
    • Yilmaz, Musa;
    • Alvarado, Yesid;
    • Montalbano, Kathryn;
    • Wade, Allison;
    • Maduike, Rita;
    • Guerrero, Julio;
    • Vaughan, Kenneth;
    • Bivins, Carol;
    • Pierce, Sherry;
    • Ning, Jing
    Publication type:
    Article
    29

    Poster: AML-204: Venetoclax Combined with FLAG-IDA Induction and Consolidation in Newly Diagnosed Acute Myeloid Leukemia.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S213, doi. 10.1016/S2152-2650(21)01338-0
    By:
    • Lachowiez, Curtis;
    • Takahashi, Koichi;
    • Loghavi, Sanam;
    • Xiao, Lianchun;
    • Kadia, Tapan;
    • Adeoti, Maria;
    • Short, Nicholas;
    • Sasaki, Koji;
    • Wang, Sa;
    • Borthakur, Gautam;
    • Issa, Ghayas;
    • Maiti, Abhishek;
    • Alvarado, Yesid;
    • Pemmaraju, Naveen;
    • Bravo, Guillermo Montalban;
    • Masarova, Lucia;
    • Yilmaz, Musa;
    • Jain, Nitin;
    • Andreeff, Michael;
    • Jabbour, Elias
    Publication type:
    Article
    30

    Oral Abstract: AML-204: Venetoclax Combined with FLAG-IDA Induction and Consolidation in Newly Diagnosed Acute Myeloid Leukemia.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S201, doi. 10.1016/S2152-2650(21)01270-2
    By:
    • Lachowiez, Curtis;
    • Takahashi, Koichi;
    • Loghavi, Sanam;
    • Lianchun Xiao;
    • Kadia, Tapan;
    • Adeoti, Maria;
    • Short, Nicholas;
    • Sasaki, Koji;
    • Sa Wang;
    • Gautam Borthakur;
    • Issa, Ghayas;
    • Maiti, Abhishek;
    • Alvarado, Yesid;
    • Pemmaraju, Naveen;
    • Bravo, Guillermo Montalban;
    • Masarova, Lucia;
    • Yilmaz, Musa;
    • Jain, Nitin;
    • Andreeff, Michael;
    • Jabbour, Elias
    Publication type:
    Article
    31
    32
    33
    34
    35

    Randomized Phase II Study of Guadecitabine (SGI-110) Based Regimens Comparing Guadecitabine 5 days (SGI5), 10 days (SGI10), 5 days + Idarubicin (SGI5 + Ida), and 5 days + Cladribine (SGI5 + Clad), in Previously Untreated Patients ≥ 70 Years with Acute Myeloid Leukemia (AML)--a Bayesian Design.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S6, doi. 10.1016/j.clml.2017.09.032
    By:
    • Naqvi, Kiran;
    • Gonzalez, Garciela Nogueras;
    • Cheung, Cora;
    • Pemmaraju, Naveen;
    • Jabbour, Elias;
    • Garcia-Manero, Guillermo;
    • DiNardo, Courtney;
    • Ohanian, Maro;
    • Jain, Nitin;
    • Koichi Takahashi;
    • Alvarado, Yesid;
    • Konopleva, Marina;
    • Xuelin Huang;
    • Cortes, Jorge;
    • Kantarjian, Hagop
    Publication type:
    Article
    36

    Outcomes with Decitabine Followed by Clofarabine, Idarubicin, and Cytarabine as Salvage Therapy for Relapsed/ Refractory Acute Myeloid Leukemia.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S3, doi. 10.1016/j.clml.2017.09.028
    By:
    • Boddu, Prajwal;
    • Jain, Nitin;
    • Ravandi, Farhad;
    • Garcia Manero, Guillermo;
    • Borthakur, Gautam;
    • Kadia, Tapan;
    • Jabbour, Elias J.;
    • Pemmaraju, Naveen;
    • Daver, Naval;
    • DiNardo, Courtney D.;
    • Konopleva, Marina;
    • Alvarado, Yesid;
    • Takahashi, Koichi;
    • Benton, Christopher;
    • Pike, Allison;
    • Pierce, Sherry;
    • Cortes, Jorge E.;
    • Kantarjian, Hagop M.
    Publication type:
    Article
    37

    The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S3, doi. 10.1016/j.clml.2017.09.027
    By:
    • Swaminathan, Mahesh;
    • Kantarjian, Hagop;
    • Daver, Naval;
    • Borthakur, Gautam;
    • Ohanian, Maro;
    • Kadia, Tapan;
    • DiNardo, Courtney;
    • Jain, Nitin;
    • Estrov, Zeev;
    • Ferrajoli, Alessandra;
    • Garcia-Manero, Guillermo;
    • Konopleva, Marina;
    • Andreeff, Michael;
    • Pemmaraju, Naveen;
    • Jabbour, Elias;
    • Alvarado, Yesid;
    • Wierda, William;
    • Pinsoy, Maria Rhona;
    • Ravandi, Farhad;
    • Cortes, Jorge
    Publication type:
    Article
    38

    Frontline Inotuzumab Ozogamicin with Low-intensity Chemotherapy (mini-hyper-CVD) in Older Patients with Acute Lymphoblastic Leukemia (ALL): Updated Results of a Phase I/II Trial.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S255, doi. 10.1016/j.clml.2017.07.019
    By:
    • Maiti, Abhishek;
    • Kantarjian, Hagop;
    • O'Brien, Susan;
    • Ravandi, Farhad;
    • Short, Nicholas;
    • Thomas, Deborah;
    • Garcia-Manero, Guillermo;
    • Daver, Naval;
    • Borthakur, Gautam;
    • Jain, Nitin;
    • Konopleva, Marina;
    • Sasaki, Koji;
    • Pemmaraju, Naveen;
    • Alvarado, Yesid;
    • Jacob, Jovitta;
    • Garris, Rebecca;
    • Thompson, Philip;
    • Cortes, Jorge;
    • Jabbour, Elias
    Publication type:
    Article
    39

    Results of Second Salvage Therapy for Acute Myeloid Leukemia in the Modern Era.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S272, doi. 10.1016/j.clml.2017.07.047
    By:
    • Simkins, Aron;
    • DiNardo, Courtney D.;
    • Kadia, Tapan;
    • Daver, Naval;
    • Pemmaraju, Naveen;
    • Naqvi, Kiran;
    • Ohanian, Maro;
    • Takahashi, Koichi;
    • Alvarado, Yesid;
    • Brandt, Mark;
    • Pierce, Sherry;
    • Konopleva, Marina;
    • Jabbour, Elias;
    • Garcia-Manero, Guillermo;
    • Cortes, Jorge;
    • Ravandi-Kashani, Farhad;
    • Kantarjian, Hagop
    Publication type:
    Article
    40

    Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage–colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia

    Published in:
    Cancer (0008543X), 2003, v. 97, n. 7, p. 1711, doi. 10.1002/cncr.11238
    By:
    • Apostolia M. Tsimberidou;
    • Hagop M. Kantarjian;
    • Jorge Cortes;
    • Deborah A. Thomas;
    • Stefan Faderl;
    • Guillermo Garcia-Manero;
    • Srdan Verstovsek;
    • Alessandra Ferrajoli;
    • William Wierda;
    • Yesid Alvarado;
    • Susan M. O'Brien;
    • Maher Albitar;
    • Michael J. Keating;
    • Francis J. Giles
    Publication type:
    Article
    41
    42
    43

    Oral Mucositis: Time for More Studies.

    Published in:
    Hematology, 2002, v. 7, n. 5, p. 281, doi. 10.1080/1024533021000037216
    By:
    • Alvarado, Yesid;
    • Bellm, Lisa A.;
    • Giles, Francis J.
    Publication type:
    Article
    44
    45

    A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents.

    Published in:
    Journal of Hematology & Oncology, 2023, v. 16, n. 1, p. 1, doi. 10.1186/s13045-023-01476-8
    By:
    • Short, Nicholas J.;
    • Muftuoglu, Muharrem;
    • Ong, Faustine;
    • Nasr, Lewis;
    • Macaron, Walid;
    • Montalban-Bravo, Guillermo;
    • Alvarado, Yesid;
    • Basyal, Mahesh;
    • Daver, Naval;
    • Dinardo, Courtney D.;
    • Borthakur, Gautam;
    • Jain, Nitin;
    • Ohanian, Maro;
    • Jabbour, Elias;
    • Issa, Ghayas C.;
    • Qiao, Wei;
    • Huang, Xuelin;
    • Kanagal-Shamanna, Rashmi;
    • Patel, Keyur P.;
    • Bose, Prithviraj
    Publication type:
    Article
    46

    Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia.

    Published in:
    Journal of Hematology & Oncology, 2023, v. 16, n. 1, p. 1, doi. 10.1186/s13045-023-01444-2
    By:
    • Kantarjian, Hagop;
    • Haddad, Fadi G.;
    • Jain, Nitin;
    • Sasaki, Koji;
    • Short, Nicholas J.;
    • Loghavi, Sanam;
    • Kanagal-Shamanna, Rashmi;
    • Jorgensen, Jeffrey;
    • Khouri, Issa;
    • Kebriaei, Partow;
    • Alvarado, Yesid;
    • Kadia, Tapan;
    • Paul, Shilpa;
    • Garcia-Manero, Guillermo;
    • Dabaja, Bouthaina;
    • Yilmaz, Musa;
    • Jacob, Jovitta;
    • Garris, Rebecca;
    • O'Brien, Susan;
    • Ravandi, Farhad
    Publication type:
    Article
    47
    48

    Cladribine, idarubicin, and cytarabine (CLIA) for patients with relapsed and/or refractory acute myeloid leukemia: A single‐center, single‐arm, phase 2 trial.

    Published in:
    Cancer (0008543X), 2025, v. 131, n. 8, p. 1, doi. 10.1002/cncr.35840
    By:
    • Goulart, Hannah;
    • Kantarjian, Hagop;
    • Borthakur, Gautam;
    • Daver, Naval;
    • DiNardo, Courtney D.;
    • Jabbour, Elias;
    • Pemmaraju, Naveen;
    • Alvarado, Yesid;
    • Atluri, Himachandana;
    • Yilmaz, Musa;
    • Haddad, Fadi G.;
    • Marx, Kayleigh R.;
    • Rausch, Caitlin;
    • Loghavi, Sanam;
    • Jain, Nitin;
    • Garcia‐Manero, Guillermo;
    • Ravandi‐Kashani, Farhad;
    • Kadia, Tapan M.
    Publication type:
    Article
    49

    Long‐term follow‐up of a phase 2 study of all‐trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia.

    Published in:
    Cancer (0008543X), 2025, v. 131, n. 1, p. 1, doi. 10.1002/cncr.35662
    By:
    • Jen, Wei‐Ying;
    • Marvin‐Peek, Jennifer;
    • Kantarjian, Hagop M.;
    • Alvarado, Yesid;
    • Borthakur, Gautam;
    • Jabbour, Elias;
    • Wierda, William;
    • Kadia, Tapan M.;
    • Daver, Naval G.;
    • DiNardo, Courtney D.;
    • Short, Nicholas J.;
    • Jain, Nitin;
    • Ferrajoli, Alessandra;
    • Kornblau, Steven;
    • Yilmaz, Musa;
    • Ohanian, Maro;
    • McCue, David;
    • Burger, Jan;
    • Hammond, Danielle;
    • Patel, Keyur
    Publication type:
    Article
    50

    Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia.

    Published in:
    Cancer (0008543X), 2024, v. 130, n. 15, p. 2652, doi. 10.1002/cncr.35317
    By:
    • Jabbour, Elias;
    • Haddad, Fadi G.;
    • Sasaki, Koji;
    • Carter, Bing Z.;
    • Alvarado, Yesid;
    • Nasnas, Cedric;
    • Nasr, Lewis;
    • Masarova, Lucia;
    • Daver, Naval;
    • Pemmaraju, Naveen;
    • Short, Nicholas J.;
    • Skinner, Jeffrey;
    • Kadia, Tapan;
    • Borthakur, Gautam;
    • Garcia‐Manero, Guillermo;
    • Ravandi, Farhad;
    • Issa, Ghayas C.;
    • Andreeff, Michael;
    • Kantarjian, Hagop
    Publication type:
    Article